yego.me
💡 Stop wasting time. Read Youtube instead of watch. Download Chrome Extension

Finding a Cancer Killer | Breakthrough


2m read
·Nov 11, 2024

NARRATOR: Working out of the University of Pennsylvania, Dr. June has been developing a new technology to leverage the immune system's T-cells to fight and kill leukemia in mice. [squeaking]

CARL JUNE: Yeah. I have been through a long journey. So I was a physician. And then gradually, I came to the conclusion that I could probably help more people through my scientific laboratory efforts than actually seeing people one at a time in a clinic. And I tell my family now that my MD stands for mouse doctor.

NARRATOR: The immune system protects you from outside invasion. If a virus, bacteria, or fungus slips into your body, the immune system responds with a coordinated attack that kills the invader, and only the invader, leaving your body intact. [chittering] This is a T-cell. This immune cell's job is to kill infected cells before they cause more damage. In theory, T-cells can be extraordinarily potent against leukemia. But there's one problem. Since cancer is effectively part of your own body, the immune system sometimes ignores these rogue cells, allowing the cancer to spread unchecked. June and his team have worked tirelessly to find a way to get the immune system to recognize and destroy all of the cancer cells in the body.

CARL JUNE: The therapy we're developing is multidisciplinary. It involves leukemia specialists. David Porter is known around the world for his treating various kinds of leukemia. It involves immunology expertise, viral vector design expertise, and then the cell culture expertise that Bruce Levine knows more about than anyone in the world, I'm quite sure. OK. I'm a professor in cancer gene therapy. And I direct the Clinical Cell and Vaccine Production Facility. And what we do is to develop, manufacture, and test cell and gene therapies to fight cancer using the patient's own immune cells that have been genetically targeted to cancer. [humming]

A CAR T-cell is a T-cell that is genetically modified in a way that allows it to see and recognize a cancer cell. A "CAR" stands for chimeric antigen receptor. It's a molecule that is synthetic. We can put it into an immune cell and genetically change the immune cell to express the CAR molecule. That function of binding activates the T-cell. And it allows it to become active, to become a killer cell, and to kill the leukemia. [explosions] [yelp] [belch] [explosion]

More Articles

View All
Changing equilibria from trade | APⓇ Microeconomics | Khan Academy
In this video, we’re going to think about how trade can alter the equilibrium price and quantity in a given market. So, what we see here, as we like to do, are very simplified examples of markets in various economies. First, we have Country A, and let’s …
Tiger Sharks' Superpowered Jaws | SharkFest | National Geographic
Tiger sharks are one of the largest predatory sharks on the planet. They feed off an extensive menu: whales, birds, even other sharks. But there’s one delicacy that takes more effort than others. Turtles! So how much jaw power does it take to crunch throu…
.38 Special vs Prince Ruperts Drop at 170,000 FPS - Smarter Every Day 169
Hey, it’s me, Destin. Welcome back to Smarter Every Day. In one of the previous episodes, we shot a .22 caliber bullet against various Prince Rupert’s Drops, and you saw it splatter against the glass. It was fascinating. Now, a lot of people had comments…
Ethical Rudeness | The Philosophy of Mencius
We live in an age in which freedom of speech and saying what we want is seen as one of the most important tries of human being. But does that make rudeness a virtue? While I think that people should have freedom of speech and that unpopular opinions shou…
A Look Inside Billionaire Seth Klarman's Portfolio
Seth Klarman is one of the most highly respected investors ever. He is a value investor and portfolio manager of the investment partnership, the Baupost Group, founded in 1983. The Baupost Group now manages $7 billion and has average returns of nearly 20%…
David Rusenko - How To Find Product Market Fit
So our next speaker and I have something in common: we both started businesses to allow people to create websites. The difference is that David’s business was massively successful. Davidenko is the founder of Weebly, which early this year sold to Square. …